References
- Armon C. Accrued somatic mutations (nucleic acid changes) trigger ALS: 2005–2015 update. Muscle Nerve. 2016;53:842–9.
- Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127–38.
- Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213:448–55.
- Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–17.
- [Graphic]The Writing Group* on behalf of the [Graphic] Edaravone (MCI-186) ALS 19 Study Group† Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
- Hardiman O, van den Berg LH. Edaravone: a new treatment for ALS on the horizon? Lancet Neurol. 2017;16:490–1.
- Moura MC, Novaes MR, Zago YS, Eduardo EJ, Casulari LA. Efficacy of stem cell therapy in amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Clin Med Res. 2016;8:317–24.
- World Medical Association Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Adopted Helsinki, Finland 1964, most recent affirmation Fortalez, Brazil 2013. http://www.wma.net/en/30publications/10policies/b3/ Accessed February 10th, 2017. Also: JAMA. 2013;310:2191–4.
- Beauchamp TL, Childress JF. Principles of biomedical ethics, 7th ed. Oxford: Oxford University Press; 2013.
- Turner RM, Swash M. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey. J Neurol Neurosurg Psychiatry. 2015;86:667–73.
- Armon C. An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology. 2003;22:217–28.
- Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007;26:1–13.
- Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808–12.
- Mayo WJ. 1910. http://history.mayoclinic.org/toolkit/quotations/the-doctors-mayo.php. Accessed February 12th 2017.